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Cardiac Function and Heart Failure
1145-117 Reduction in Regional Myocardial Function Is 
Associated With Concentric Left Ventricular 
Remodeling: Multi-Ethnic Study of Atherosclerosis
Boaz D. Rosen, Thor Edvardsen, David Bluemke, Li Pen, Michael Jerosch-Herold, Sinha 
Shantanu, Shenghan Lai, Joao Lima, Johns Hopkins Hospital, Baltimore, MD
Background: Left ventricular hypertrophy is a risk factor for heart failure, but the transition
from regional myocardial dysfunction, compensatory remodeling and global dysfunction
has not been thoroughly clarified. Therefore, we investigated the association between LV
remodeling and regional LV function expressed as peak systolic circumferential strain
(Ecc) in participants of the Multi-Ethnic Study of Atherosclerosis (MESA).
Methods: Peak Ecc from 441 tagged MR studies was determined by Harmonic Phase
(HARP) tool, and its relationship with the degree of concentric remodeling expressed by
LV mass/ end diastolic volume (M/V) ratio was studied. Regions were defined by coro-
nary territories.
Results: In both genders, reduced strain was seen in the highest quartile of M/V ratio
when compared to lower quartiles (-13.2 vs -15.3, p<0.01). This decrease was regionally
nonuniform and was more pronounced in the left anterior descending (LAD) region (fig-
ure, *p<0.01). However, it was statistically significant in all regions. Decrease from the
first three quartiles to the fourth quartile in LAD, right (RCA)and left circumflex (LCX)
regions was 15.3%, 12.3% 10.3%, respectively (p<0.05 for all regions).
Conclusion: Concentric remodeling is associated with reduced systolic regional function
in asymptomatic individuals. Decrease in function is more prominent in the LAD territory
but is also present in the RCA and LCX regions. It may reflect transition from compensa-
tory remodeling to myocardial failure.
. 
1145-118 Torasemide Inhibits Transcardiac Extraction of 
Aldosterone in Patients With Congestive Heart Failure
Takayoshi Tsutamoto, Chitose Ishikawa, Keijin Ohno, Hiroshi Sakai, Atsuyuki Wada, 
Masato Ohnishi, Minoru Horie, Shiga University of Medical Science, Otsu, Japan
Background. We reported that mineralocorticoid receptor antagonist spironolactone
inhibits the transcardiac extraction of aldosterone (ALD) in patients with congestive heart
failure (CHF). In the TORIC (TORasemide In patients with Congestive heart failure in
NYHA class II and III) study, torasemide had more beneficial effect on mortality and mor-
bidity of CHF patients than furosemide. However, the mechanism of the beneficial effect
of torasemide remains unknown. Method. To evaluate whether the torasemide has an
aldosterone (ALD) receptor antagonist, we studied 50 CHF patients who had been ran-
domly administered furosemide (n=25) or torasemide (n=25). Patients who received
spironolactone were excluded in this study. Results. There was no difference of patients
characteristics and other treatments between the two groups. There was no difference of
NYHA functinal class, left ventricular ejection fraction (35±9 vs. 33±10%), or plasma lev-
els of ALD and brain natriuretic peptide (BNP) (372±91 vs. 315±74 pg/mL) in the aortic
root (AO) between the two groups. In the furosemide group, plasma ALD was signifi-
cantly lower in the coronary sinus (CS) than in the AO (96±11 vs. 75±12 pg/mL,
p<0.001), suggesting that ALD is extracted through the heart. In contrast, there was no
difference of plasma ALD between the AO and CS in the torasemide group (83±11 vs.
78±12 pg/mL, p=0.17) and the transcardiac gradient of ALD[ALD (AO-CS)] was signifi-
cantly lower in the torasemide group than the furosemide group (4.6±3 vs. 16±4 pg/mL,
p<0.05), suggesting that the extraction of ALD through the heart is inhibited by
torasemide. In addition, plasma procollagen type III aminoterminal peptide, a biochemi-
cal marker of fibrosis, level in the CS is significantly lower in in the torasemide group than
the furosemide group (0.5±0.03 vs. 0.65±0.08 U/mL, p<0.05). Conclusion. These find-
ings suggest that torasemide has an ALD receptor antagonist in the failing heart in
patients with CHF.
1145-119 Tissue Inhibitor of Matrix Metalloproteinase-1 Is a 
Marker of Left Ventricular Diastolic Dysfunction in 
Diabetic Heart Disease
Sern H. Lim, Muzahir H. Tayebjee, Robert J. MacFadyen, Gregory Y. Lip, Haemostasis, 
Thrombosis and Vascular Biology Unit, City Hospital, Birmingham, United Kingdom
Background: The high prevalence of diastolic dysfunction in diabetes may be related to
abnormal cardiac extracellular matrix composition, regulated by matrix metalloprotein-
ases (MMP) and tissue inhibitors of metalloproteinases (TIMP). We hypothesised that
plasma MMP-9, TIMP-1 & -2 are related to diastolic dysfunction in patients with diabetes.
Methods: We measured plasma MMP-9, TIMP-1 & -2 by ELISA in 56 patients with dia-
betes and 16 comparable controls. Early (E) and atrial (A) diastolic mitral inflow velocity
was measured with pulse wave Doppler and early mitral annular velocity (E’), an index of
diastolic relaxation, with tissue Doppler on transthoracic echocardiogram. The ratio of E
to A (E/A) and E to E' (E/E', an index of left ventricular filling pressure) were derived from
these measurements.
Results: Patients with diabetes had lower E’, higher E/E’ ratio and higher TIMP-1 levels
(Table). There was no significant difference in E/A ratio, MMP-9 and TIMP-2 levels
between patients and controls. E’ (r = -0.31, p=0.02) but not the ratio of E/E’ (p=0.061)
correlated negatively with TIMP-1. There were no significant correlations between TIMP-
1 with age, systolic or diastolic blood pressure and HbA1c. TIMP-1 remained a predictor
of E’ on multivariate regression analysis (p=0.002).
Conclusion: In diabetes, raised circulating levels of TIMP-1 is associated with abnormal
diastolic function. This suggests that TIMP-1 may be involved in abnormal cardiac extra-
cellular matrix turnover in diabetes.
1145-120 Left Ventricular Mass Reduction in Type 1 Diabetes 
Mellitus
Larry A. Weinrauch, John A. D'Elia, Ray E. Gleason, Andrew Burger, Annette Lee, Joslin 
Diabetes Center, Boston, MA, Beth Israel Deaconess Medical Center, Boston, MA
Background: Improvement in glucose control of patients with type 1diabetes (DM1) has
been demonstrated to blunt the progression of microvascular complications (retinopathy,
nephropathy). A relationship between renal dysfunction, level of advanced glycated end
products (AGE) and microvascular complications has recently been shown. Last year we
reported that a fall in HbA1c was also associated with a reduction in left ventricular mass
(LVM) and LV septal thickness (LVS). We now postulate that reduction of LVM and AGE is
less likely to occur when renal dysfunction progresses.
Method: 17 DM1 patients (pts) with proteinuria were followed for 12 months on an inten-
sive glycemia/hypertension control program with repeated ambulatory blood pressure
monitoring, echocardiogram, serum creatinine, creatinine clearance and AGE.
Results: Of the 17, ten pts decreased LV mass (LVM) >= 20 g (mean = 46 ± 7 g), during
the study, 7 did not (mean increase = 20 ± 12 g, p = 0.0002). These two LVM groups dif-
fered with respect to change in AGE (p = 0.01), but not HbA1c. MAP (94, 107 baseline, p
= 0.0045; 98, 103 12 months, p = ns; delta 4.45, -3.79, p = 0.0186) was similar in all
groups at the end of the study. Eight pts decreased septal (LVS) thickness >= 1mm dur-
ing the study, 9 did not (-1.75 ± 0.25 vs. 0.56 ± 0.18, p = 0.0001). These two LVS groups
differed with respect to change in HbA1c (p < 0.05), but not in AGE or MAP.
The 10 pts with a decrease in LVM maintained creatinine clearance (Ccreat) at 63 ml/
min. The 7 pts without a decrease in LVM changed Ccreat from 54 to 40 (p < 0.02). The 8
pts with decreased LVS changed Ccreat from 65 to 57 ml/min. The 9 pts without a
decrease in LVS changed Ccreat from 54 to 50 ml/min (p = ns)
Conclusion: Decreases in LVM and LVS as a result of glycemic and blood pressure con-
trol appear to be related to preservation of renal function in DM1. In a total group of
patients that diminished LVM with glycemic and blood pressure control, we noted that
LVM decreased preferentially in pts with stable renal function.
1145-121 Prognostic Value of Plasma Erythropoietin on Mortality 
in Patients With Chronic Heart Failure
Peter Van der Meer, Adriaan A. Voors, Erik Lipsic, Tom D. Smilde, Wiek H. Van Gilst, Dirk 
J. Van Veldhuisen, University Hospital Groningen, Groningen, The Netherlands, 
University of Groningen, Groningen, The Netherlands
Background
Anemia is common and is associated with mortality in chronic heart failure (CHF). Eryth-
ropoietin (EPO) is a hematopoietic growth factor, upregulated in anemic conditions. Its
prognostic value in CHF patients is unknown.
Methods and results
In 74 patients with CHF (age 60±7 years, Left Ventricular Ejection Fraction (LVEF)
0.32±0.01, peak oxygen consumption (VO2) 19.1±0.6, (mean±SEM) and in 15 control
patients, plasma concentrations of EPO were prospectively assessed. During a mean fol-
low-up of 2.6 years, 22 patients (30%) died. Anemia (hemoglobin levels <12 g/dl) was
present in 12.9% of the patients. We observed only a mild inverse correlation between
the logarithm of EPO log(EPO) and hemoglobin levels (r2=0.08, p = 0.02), which was
much more pronounced in the control group r2=0.44, p=0.007). There was a significant
association between log(EPO) and BNP levels (r2=0.27, p < 0.001). Multivariate analysis
showed that plasma EPO (p=0.02), hemoglobin levels (p=0.002) and age (p=0.02) were
independent predictors of survival in this CHF population.
Conclusion
Table: data as mean ± SD or median (IQR)
Patients
(n=56)
Controls
(n=16)
P value
Age (years)
SBP (mmHg)
DBP (mmHg)
HbA1c (%)
E’ (cm/s)
E/A
E/E’
MMP-9 (ng/ml)
TIMP-1 (ng/ml)
TIMP-2 (ng/ml)
68 ± 6
139 ± 17
76 ± 9
7.6 ± 1.5
0.07 ± 0.01
0.87 ± 0.19
10.8 ± 1.2
45 (32 – 50)
450 (370 – 525)
140 (140 – 185)
65 ± 7
128 ± 16
78 ± 8
5.5 ± 0.2
0.09 ± 0.02
0.89 ± 0.15
9.3 ± 1.9
37 (31 – 42)
380 (300 – 479)
150 (130 – 178)
0.23
0.02
0.63
<0.001
0.007
0.21
0.002
0.48
0.037
0.78
